Ticker

CEO, Brad Hauser, discusses building clinical credibility through rigorous science and peer-reviewed engagement THE WOODLANDS, TX, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced the release of its latest CEO Corner segment featuring President and Chief…

THE WOODLANDS, TX, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that Clarke Wilkirson, PhD, Clinical Development Engineer II, will present new long-term clinical data at the Society of Surgical Oncology (SSO) 2026 Annual Meeting, happening March 5-7, 2026,…

Autonomix Medical, Inc. (NASDAQ: AMIX - Get Free Report) saw a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 658,692 shares, a drop of 57.3% from the December 31st total of 1,543,188 shares. Currently, 10.2% of the shares of the stock are short sold. Based

THE WOODLANDS, TX, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that final clinical data evaluating its transvascular radiofrequency (RF) ablation approach for pain mitigation in pancreatic adenocarcinoma will be presented at the Society of Interventional…

Autonomix Medical, Inc. (NASDAQ: AMIX - Get Free Report) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 1,543,188 shares, a growth of 1,052.8% from the December 15th total of 133,864 shares. Based on an average daily trading volume, of 12,719,755